Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients

Ashraf Fakhari, Esmaeil Gharepapagh, Shahram Dabiri, Neda Gilani, Ashraf Fakhari, Esmaeil Gharepapagh, Shahram Dabiri, Neda Gilani

Abstract

Background: Cancer antigen 15-3 (CA15-3) is a common tumor marker and the serum level of this tumor marker is evaluated during the treatment period (periodically) in breast cancer patients. Assuming that the elevated serum levels of this tumor marker can be a potential risk, this study was conducted to determine the association between CA15-3 and bone metastasis and CA15-3 and metastasis spreading rate in breast cancer patients. Methods: In this study, 70 women with the mean of age 51.69 (10.77) years who suffered from breast cancer were studied by performing both bone scintigraphy and measuring CA15-3. Independent sample t test, Fisher's exact test, Spearman rho correlation, and logistic regression were used for inferential section. To determine the new cross section, Roc curve and coordinates of the curve were applied. Also, significance level was set at p<0.05. Data were analyzed by SPSS 16 software. Results: There was no difference among patients in age (p=0.123). Assuming the CA15-3 (≥ 30 U/mL) as a potential risk, there was no association between CA15-3 and bone metastases (p=0.167). Based on Spearman's rank correlation coefficient, there was no significant correlation between CA15-3 and metastasis spreading rate (r=-0.07, p=0.851). Based on ROC curve and Youden's J statistic index, the new cutoff was pointed at CA15-3 ≥21.76 Unit/mL, which correlated with bone metastases (p<0.001). Conclusion: This study found a decreased cutoff point at CA15-3 (≥21.76) against 30 (routine value). Based on CA15-3 (≥21.76), there was a correlation between bone metastases and CA15-3, indicating that patients with CA15-3 (≥21.76) were most likely to experience bone metastases.

Keywords: Bone metastases; Bone scintigraphy; Breast cancer; CA15-3.

© 2019 Iran University of Medical Sciences.

Figures

Diagram 1
Diagram 1
Graph 1
Graph 1
Graph 2
Graph 2
Graph 3
Graph 3
Diagram 2
Diagram 2

References

    1. Howlader N, Noone AM, Krapcho M. (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute. Bethesda, MD, 2012.
    1. Fakhari A, Jalilian AR, Yousefnia H, Johari-Daha F, Mazidi M, Khalaj A. Development of 166Ho-pamidronate for bone pain palliation therapy. J Radioanal Nuucl Chem. 2014 Sep;303(1):743–750.
    1. American Cancer Society. Breast Cancer Facts &Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.
    1. Munazzah Rahmani M, Sulma Mohammed S. Breast cancer metastasis and the lymphatic system. Oncol Lett. 2015 Sep;10(3):1233–1239.
    1. Kirsten Steinauer K, Huang DJ, Eppenberger-Castori S, Esther Amann E, Güth U. Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy. J Bone Oncol. 2014 May;3(2):54–60.
    1. Gillian Bedard G, Edward Chow E. The failures and challenges of bone metastases research in radiation oncology. J Bone Oncol. 2013 Jun;2(2):84–88.
    1. Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, Costa L. Bone metastasis risk factors in breast cancer. Ecancermedicalscience. 2017;11:715.
    1. Lu X, Kang Y. Epidermal growth factor signalling and bone metastasis. Br J Cancer. 2010 Feb 2;102(3):457–461.
    1. Padera TP, Meijer EF, Munn LL. The Lymphatic System in Disease Processes and Cancer Progression. Annu Rev Biomed Eng. Author manuscript; available in PMC 2017 Jul 11.
    1. Giulio Maccauro G, Spinelli MS, Mauro S, Perisano C, Graci C, Rosa MA. Physiopathology of Spine Metastasis. Int J Surg Oncol. 2011;2011:107969.
    1. Peepre K. 99mTc-MDP Bone Scan In the Detection of Bone Metastases in Breast cancer . IOSR-JDMS. 2014 Jan;13(1):82–86.
    1. Bae KU, Kim SH, Hyun Oo J, Sun Sohn H, Chung SK. Comparison between 3-phase bone scan and MRI in diagnosis of osteomyelitis . J Nucl Med. 2010 May;2:1635.
    1. Echeverria L, Drudge-Coates L, Wilkins C, H H. Muir G Bone Scan Is of Doubtful Value as a First Staging Test in the Primary Presentation of Prostate Cancer. ISRN Oncol. 2012;2012:585017.
    1. Fejzić H, Mujagić S, Azabagić S, Burina M. Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad. 2015;44(1):39–46.
    1. Guidelines for basic MRI of suspected bone and soft tissue tumours, The Scandinavian Sarcoma Group 2012.
    1. Geng B, Liang MM, Xiao YE, Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015 Jan;3(1):232–236.
    1. Ghadge M, Naik P, Tiwari B, Hegde R, Matale T . Matale T A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma. Indian J Clin Biochem. 2012 Jan;27(1):97–99.
    1. He ZY, Xun Li X, Chen QS, Sun JY, Li FY, San-Gang Wu SG, Lin HX. Elevated serum carcinoembryonic antigen and CA15-3 levels and the risk of site-specific metastases in metastatic breast cancer. Transl Cancer Res. 2016 Oct;5(5):529–537.
    1. Niedera C, Dalhauga A, Hauklanda E, Mannsakera B, Adam Pawinskia A. Prognostic Impact of the Tumor Marker CA 15-3 in PatientsWith Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. J Clin Med Res. 2017;9(3):183–187.
    1. Geng BENG, Liang MM, Ye XB, Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015 Jan;3(1):232–236.
    1. Fatima H, Maqbool A, Siddiqui M, Haider G, Sohail H, Saleem O, Ahmed A. Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer. JCTI. 2016;4(3):1–12.
    1. Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B , Gelmon KA. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome . Ann Oncol. 2012 May;23:338–345.
    1. Kabel A. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017 Apr;3(1):5–11.
    1. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010 Dec 14;411(23-24):1869–74.
    1. Fu Y, Hui Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit. 2016;22:3154–3162.
    1. Ali HQ, Mahdi NK, Al-Jowher MH. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. J Pak Med Assoc. 2013 Sep;63(9):1138–41.
    1. Mudduwa L, LK LK, Wijayaratne G, Peiris H, Gunasekera S, Abeysiriwardhana D, Liyanage N. Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? Int J Womens Health. 2018;10:329–335.
    1. Incoronato M, Peppino Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A, Nicolai E. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients . BMC Cancer. 2014 May;14:356.
    1. Montravers F, Younsi N, Rousseau C, Philippe C, Seddiki M, Uzan S. et al. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer. Anticancer Res. 1997 May-Jun;17(3B):1683–6.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner